Bradley A. McGregor, MD, discusses the clinical significance of the updated COSMIC-021 data, how these findings support the continued investigation of IO/TKI combinations in non–clear cell renal cell carcinoma, and other efforts underway to better care for patients with varying histological subtypes of the disease.
Read More
FIDES-02 Data Fail to Support the Development of Derazantinib in Metastatic Urothelial Cancer
April 25th 2023Andrea Necchi, MD, discusses the efficacy and safety data reported from the FIDES-02 study, explains the clinical relevance of these data despite the trial’s negative result, and highlights several other influential studies presented at the 2023 Genitourinary Cancers Symposium.
Read More
AZD3759 Elicits Responses in Untreated EGFR-Mutant NSCLC With CNS Metastases
April 25th 2023AZD3759 elicited clinical responses and had an acceptable toxicity profile when administered at a dose of 200 mg twice daily in patients with untreated EGFR-mutant non–small cell lung cancer and central nervous system metastases, according to data from the phase 2 TRUMP trial.
Read More
TRAVERSE Study Shows Preliminary Efficacy and Safety of ALLO-316 in Advanced Clear Cell RCC
April 25th 2023Samer A. Srour, MB ChB, MS, explains the unique construction of ALLO-316, the potential for ALLO-316 to address an unmet need in patients with clear cell renal cell carcinoma, and how early data from the TRAVERSE study support the continued investigation of ALLO-316 in patients with CD70-expressing tumors.
Read More
Ursula A. Matulonis highlights previous data from the phase 3 ENGOT-OV16/NOVA trial initial readout and subsequent preplanned overall survival analysis, discusses new findings from the final analysis, and emphasizes how these data clarify some of the study’s limitations and reinforce the importance of adhering to the adjusted FDA label for niraparib in recurrent ovarian cancer.
Read More
Ribociclib Plus Letrozole Has Activity in Recurrent Low-Grade Serous Ovarian Cancer
April 24th 2023Brian M. Slomovitz, MD, discusses key efficacy and safety data seen with ribociclib and letrozole in the GOG 3026 trial and planned efforts to identify associated biomarkers and pursue FDA approval for the combination in advanced, recurrent low-grade serous ovarian cancer.
Read More
Joshua K. Sabari, MD, shares how the unique pharmacokinetics and mechanism of action for LY3537982 supported its investigation in the LOXO-RAS- 20001 study, findings presented at AACR, and how this research could address unmet needs in patients with KRAS G12C–mutant solid tumors.
Read More
Phase 2 Data Support Development of Lasofoxifene in ESR1-mutant, ER+/HER2– Breast Cancer
April 19th 2023Jane Lowe Meisel, MD, discusses previously reported data from the ELAINE-1 and ELAINE-2 trials, their significance within the ESR1-mutant, ER-positive, HER2-negative breast cancer treatment paradigm, and the purpose of the ongoing ELAINE-3 trial.
Read More
MOUNTAINEER and DESTINY-CRC01 Trials Expand Second-Line Options for HER2+ mCRC
April 15th 2023Alaa Muslimani, MD, discusses the significance of the phase 2 DESTINY-CRC01 and MOUNTAINEER-03 trials on HER2-positive metastatic colorectal cancer treatment in the second line, efforts to expand the use of these agents in earlier disease settings, and the need for more robust clinical data and larger investigations for this population.
Read More
Shannon N. Westin, MD, MPH, FACOG, shares preclinical data that provided the impetus for the SOLAR trial of olaparib and selumetinib in patients with RAS-mutated gynecologic cancers, key findings from the dose-escalation and -expansion portions of the research, and next steps with the combination.
Read More
Practice-Changing Trials Expand Armamentarium and Improve Guidance in Advanced Breast Cancers
April 13th 2023Several landmark trials have led to FDA approval milestones across all breast cancer subtypes in the past 5 years, each continuing to change the navigation of treatment approaches in clinical practice.
Read More
Research on Current and Emerging HER2-targeted Agents Continues to Advance Breast Cancer Treatment
April 11th 2023Cynthia X. Ma, MD, PhD, discusses updates in triple-negative breast cancer treatment, recent data on HER2-targeted agents in metastatic and early-stage HER2-positive breast cancer, and the role of CDK4/6 inhibitors and oral selective estrogen receptor degraders in hormone receptor–positive disease.
Read More
Erdafitinib Intravesical Delivery System Under Exploration in Select FGFR+ NMIBC or MIBC
April 10th 2023Antoni Vilaseca, MD, PhD, explains the unique mechanism of the TAR-210 erdafitinib delivery system and expands on the key objectives, trial design, and patient characteristics of a phase 1 trial evaluating TAR-210 in patients with recurrent NMIBC or MIBC harboring select FGFR mutations or fusions.
Read More
MVP-S Plus Low-Dose Cyclophosphamide Elicits Robust Responses in Recurrent Ovarian Cancer
April 10th 2023Oliver Dorigo, MD, PhD, explains how MVP-S leverages the DPX platform to produce persistent anti-survivin immune infiltration, highlights the antitumor activity and safety observed with the combination when given to patients with recurrent ovarian cancer, and describes additional research efforts underway.
Read More
Low RNA Expression of RAD51, BRCA1 Associated With Prolonged OS in HRP CRC
April 8th 2023Daniel Walden, MD, discusses the goal of analyzing RNA expression of wild-type HR genes in CRC, the importance of evaluating the benefit of chemotherapeutic approaches in patients with HRP CRC based on RNA expression levels, and the next steps for validating and implementing these findings in clinical practice.
Read More
Effective Detection of MRD May Support Earlier Implementation of ctDNA Testing in CRC
April 6th 2023Stacey A. Cohen, MD, discusses the advantages and limitations of ctDNA as a biomarker for detecting minimal residual disease , real-world data on the relationship between fluctuating cfDNA levels and ctDNA detection, and how implementing ctDNA testing earlier to identify minimal residual disease could serve as a prognostic tool in clinical practice.
Read More
Recent Approvals Support Continued Research on New and Emerging ADCs Across Breast Cancer Subtypes
April 6th 2023Stephanie L. Graff, MD, gives an overview of recently approved ADCs in TNBC and HR-positive, HER2-negative breast cancer, as well as the importance of continued research with these agents in the first-line setting.
Read More
TALAPRO-2 Data Underscore Potential of Talazoparib Plus Enzalutamide in mCRPC
March 29th 2023Neeraj Agarwal, MD, discusses preclinical data that supported the launch of the TALAPRO-2 trial and key efficacy and safety data on the use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer irrespective of homologous recombination repair mutational status.
Read More
Tivozanib Plus Atezolizumab Under Investigation in Immunologically Cold Tumors
March 24th 2023The safety and efficacy of the immune checkpoint inhibitor atezolizumab plus the VEGF TKI tivozanib is being investigated in patients with unresectable or metastatic castrate-resistant prostate cancer, as well as those with several other immunologically cold tumors as part of the phase 1b/2 IMMCO-1 trial.
Read More
Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations
March 22nd 2023Siamak Daneshmand, MD, shed light on the phase 2 THOR-2 study evaluating different cohorts of patients with recurrent NMIBC, key findings from cohorts 2 and 3, and how ongoing research seeks to move the needle forward with novel drug delivery methods.
Read More
Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung Cancer
March 20th 2023Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.
Read More
Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL
March 15th 2023Nirav N. Shah, MD, explains the choice to evaluate LV20.19 CAR in MCL, key efficacy and safety data from the follow-up study of this agent, and ongoing efforts to potentially expand its use across other B-cell malignancies.
Read More
Updated MAGNITUDE Data Support Niraparib Combination in mCRPC and HRR Gene Alterations
March 8th 2023Eleni Efstathiou, MD, PhD, expands on the updated interim data from the MAGNITUDE trial and sheds light on the utility of PARP inhibitor combinatorial strategies in patients with mCRPC and HRR gene alterations.
Read More
Enfortumab Vedotin Plus Pembrolizumab May Address Unmet Need in Advanced Urothelial Cancer
March 2nd 2023Jonathan E. Rosenberg, MD, discusses key safety and efficacy data from the EV-103 trial supporting supplemental biologics license applications seeking FDA approval of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer.
Read More